Keymed Biosciences, Inc. (2162) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2162 Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Keymed

Biosciences, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2162 Stock 12 Month Forecast

Average Price Target

HK$89.83

▲(43.04% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Keymed Biosciences, Inc. in the last 3 months. The average price target is HK$89.83 with a high forecast of HK$93.50 and a low forecast of HK$82.07. The average price target represents a 43.04% change from the last price of HK$62.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"HK$29","94":"HK$94","45.25":"HK$45.3","61.5":"HK$61.5","77.75":"HK$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":93.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$93.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$89.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$82.07</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,45.25,61.5,77.75,94],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.25,62.80769230769231,65.36538461538461,67.92307692307692,70.48076923076923,73.03846153846153,75.59615384615384,78.15384615384616,80.71153846153845,83.26923076923077,85.82692307692307,88.38461538461539,90.9423076923077,{"y":93.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.25,62.52538461538462,64.80076923076923,67.07615384615384,69.35153846153847,71.62692307692308,73.90230769230769,76.17769230769231,78.45307692307692,80.72846153846154,83.00384615384615,85.27923076923076,87.55461538461537,{"y":89.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.25,61.92846153846154,63.606923076923074,65.28538461538461,66.96384615384615,68.6423076923077,70.32076923076923,71.99923076923076,73.6776923076923,75.35615384615384,77.03461538461538,78.71307692307693,80.39153846153846,{"y":82.07,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.5,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.5,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.65,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$93.50

Average Price TargetHK$89.83

Lowest Price TargetHK$82.07

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

KeyBanc

Not Ranked

KeyBanc

HK$82.07

Buy

30.68%

Upside

Reiterated

11/29/25

KeyBanc Sticks to Its Buy Rating for Keymed Biosciences, Inc. (2162)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$91.08

Buy

45.03%

Upside

Reiterated

11/25/25

Huatai Securities Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$90.89→HK$91.08

Buy

45.03%

Upside

Reiterated

11/05/25

Keymed Biosciences, Inc. (2162) Gets a Buy from Huatai Securities

Honglin Yan

Goldman Sachs

Not Ranked

Goldman Sachs

HK$92.67

Buy

47.56%

Upside

Initiated

11/02/25

Keymed Biosciences' Strategic Positioning and Stapokibart's Market Potential in Biotech Sector

Jack Lin

Morgan Stanley

HK$56→HK$93.5

Buy

48.89%

Upside

Reiterated

09/22/25

Morgan Stanley Sticks to Its Buy Rating for Keymed Biosciences, Inc. (2162)Morgan Stanley analyst Jack Lin raised the price target on Keymed Biosciences Inc (2162:HK) to HK$93.50 (from HK$56.00) while maintaining a Overweight rating.

Unknown Analyst

SPDB

Not Ranked

SPDB

HK$77

Buy

22.61%

Upside

Reiterated

08/29/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$90.89

Buy

44.73%

Upside

Reiterated

08/28/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$78

Buy

24.20%

Upside

Reiterated

08/28/25

Unknown Analyst

Citi

Not Ranked

Citi

HK$85

Buy

35.35%

Upside

Reiterated

08/28/25

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$78

Buy

24.20%

Upside

Reiterated

08/28/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$85

Buy

35.35%

Upside

Reiterated

08/27/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$56.05

Buy

-10.75%

Downside

Reiterated

04/09/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$56.05

Buy

-10.75%

Downside

Reiterated

03/26/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$57

Buy

-9.24%

Downside

Reiterated

03/26/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$54.91

Buy

-12.56%

Downside

Reiterated

01/13/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

KeyBanc

Not Ranked

KeyBanc

HK$82.07

Buy

30.68%

Upside

Reiterated

11/29/25

KeyBanc Sticks to Its Buy Rating for Keymed Biosciences, Inc. (2162)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$91.08

Buy

45.03%

Upside

Reiterated

11/25/25

Huatai Securities Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$90.89→HK$91.08

Buy

45.03%

Upside

Reiterated

11/05/25

Keymed Biosciences, Inc. (2162) Gets a Buy from Huatai Securities

Honglin Yan

Goldman Sachs

Not Ranked

Goldman Sachs

HK$92.67

Buy

47.56%

Upside

Initiated

11/02/25

Keymed Biosciences' Strategic Positioning and Stapokibart's Market Potential in Biotech Sector

Jack Lin

Morgan Stanley

HK$56→HK$93.5

Buy

48.89%

Upside

Reiterated

09/22/25

Unknown Analyst

SPDB

Not Ranked

SPDB

HK$77

Buy

22.61%

Upside

Reiterated

08/29/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$90.89

Buy

44.73%

Upside

Reiterated

08/28/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$78

Buy

24.20%

Upside

Reiterated

08/28/25

Unknown Analyst

Citi

Not Ranked

Citi

HK$85

Buy

35.35%

Upside

Reiterated

08/28/25

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$78

Buy

24.20%

Upside

Reiterated

08/28/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$85

Buy

35.35%

Upside

Reiterated

08/27/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$56.05

Buy

-10.75%

Downside

Reiterated

04/09/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$56.05

Buy

-10.75%

Downside

Reiterated

03/26/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$57

Buy

-9.24%

Downside

Reiterated

03/26/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$54.91

Buy

-12.56%

Downside

Reiterated

01/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Keymed Biosciences, Inc.

1 Month

xxx

Success Rate

0/1 ratings generated profit

Average Return

-4.50%

reiterated a xxx

rating 12 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -4.50% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+19.60%

reiterated a xxx

rating 12 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +19.60% per trade.

1 Year

Jack LinMorgan Stanley

Success Rate

0/1 ratings generated profit

Average Return

-21.10%

reiterated a buy rating 3 months ago

Copying Jack Lin's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -21.10% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+82.90%

reiterated a xxx

rating 12 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +82.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2162 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2162 has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 2162 average Analyst price target in the past 3 months is 89.83.

Each month's total comprises the sum of three months' worth of ratings.

2162 Financial Forecast

2162 Earnings Forecast

The previous quarter’s earnings for 2162 were -HK$0.33.

2162 Sales Forecast

The previous quarter’s earnings for 2162 were HK$535.73M.

2162 Stock Forecast FAQ

What is HK:2162’s average 12-month price target, according to analysts?

Based on analyst ratings, Keymed Biosciences, Inc.’s 12-month average price target is 89.83.

What is HK:2162’s upside potential, based on the analysts’ average price target?

Keymed Biosciences, Inc. has 43.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Keymed Biosciences, Inc. a Buy, Sell or Hold?

Keymed Biosciences, Inc. has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Keymed Biosciences, Inc.’s share price target?

The average share price target for Keymed Biosciences, Inc. is 89.83. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$93.50 ,and the lowest forecast is HK$82.07. The average share price target represents 43.04% Increase from the current price of HK$62.8.

What do analysts say about Keymed Biosciences, Inc.?

Keymed Biosciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Keymed Biosciences, Inc.?

To buy shares of HK:2162, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Keymed Biosciences, Inc. (2162) Stock Forecast & Price Target

2162 Analyst Ratings

2162 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Keymed Biosciences, Inc.

2162 Analyst Recommendation Trends

2162 Financial Forecast

2162 Earnings Forecast

2162 Sales Forecast

2162 Stock Forecast FAQ

Detailed List of Analyst Forecasts